Perkovic V, et al. Management of patients with diabetes and CKD: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 90:1175–1183.
Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:2669–2701.
de Boer IH. The expanding resume of SGLT2 inhibitors. Lancet Diabetes Endocrinol 2019; 7:585–587.
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.
Tuttle KR. SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. Lancet Diabetes Endocrinol 2019; 7:414–415.
American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 [Suppl 1]:S71–S80.